Genedata Biopharma Partner Symposium 2024
Agenda
| Day 1 — Wednesday, March 6, 2024 | |||||||
| Plenary Session | |||||||
| 8:30–9:00 | Registration & Welcome Coffee Hyperion Hotel Basel, Messeplatz 12, Basel, Switzerland | ||||||
| 9:00–9:10 | Opening Remarks Jana Hersch, Head of Corporate Scientific Engagement, Genedata, Boston, MA, USA | ||||||
| 9:10–9:30 | Work Smarter, Not Harder: Leveraging Data to Increase Efficiency Othmar Pfannes, CEO, Genedata, Basel, Switzerland | ||||||
| 9:30–10:00 | Evolution of the Genedata Biologics Ecosystem at Pfizer: RNA and Beyond Joel Bard, Associate Research Fellow BioMedicine Design, Pfizer, Cambridge, MA, USA | ||||||
| 10:00–10:30 | Genedata Expressionist at the Biologics Research Center, Novartis Basel: Automating and Digitalizing MS Analytics Patrick Schindler, Senior Principal Scientist, Novartis, Basel, Switzerland | ||||||
| 10:30–11:00 | Break | ||||||
| 11:00–11:30 | Embracing Change: Digitalizing Antibodies, Cell & Gene Therapies, and More at AstraZeneca Carl Matthews, Principal Scientist Biologics Engineering, AstraZeneca, Great Abington, United Kingdom | ||||||
| 11:30–12:00 | Digitalizing ADC Workflows with Genedata at Merck Sameh Eid, Principal Scientist Research Informatics, Merck, Darmstadt, Germany | ||||||
| 12:00–12:30 | Streamlining Lab Execution Workflows with Genedata Rik Rademaker, Director Cell and Molecular Sciences, Genmab, Utrecht, The Netherlands | ||||||
| 12:30–2:00 | Lunch Hyperion Hotel Basel | ||||||
| Breakout Sessions | |||||||
| BIOTHERAPEUTICS DISCOVERY & DEVELOPMENT Biologics & Bioprocess | ASSAY ANALYSIS & MANAGEMENT Screener | MASS-SPEC DATA ANALYSIS Expressionist | PRECISION MEDICINE Profiler | NGS-BASED DEVELOPMENT & BIOSAFETY Selector | |||
| 2:00–2:30 | Genedata Biologics at the Center of Sanofi’s Large Molecules Research | High-Throughput Screening of NANOBODY® Molecules Using a Genedata Screener – Biologics Integrated Workflow | Genedata at Janssen: A Brief History, Current and Future Directions with Focus on Genedata Expressionist | From Lab Automation to Data Standardization and Modeling | From Sequences to Insights: Genetic Characterization of Cell Lines Using NGS Benjamin Lindner, Senior Data Scientist, Boehringer Ingelheim, Biberach, Germany | ||
| 2:30–3:00 | Leveraging Genedata Biologics in the Discovery and Characterization of TCRs for Adoptive Cell Therapy Lisa Eisenberg, Senior Scientist Machine Learning, Immatics Biotechnologies, Tübingen, Germany | Efficient Analysis of Drug Combination in Oncology Therapeutic Discovery | Peptide Mapping for the Masses: Rolling Out Data Processing to Less Experienced Users Will Burkitt, Associate Director, UCB, Slough, United Kingdom | Expanding the Genedata Biopharma Platform with Self-Service Data Science Andreas Biegert, Software Engineering Lead, Genedata, Munich, Germany | Path to Fully Automated NGS Assays with Playbooks Ludwig Macko, Head of Genedata Selector Development, Genedata, Basel, Switzerland | ||
| 3:00–3:30 | A Lean and Smart Approach for Setting Up an Antibody Development Platform Gregory Mouret, USP Scientist, Ferring Biologics Innovation Centre, Lausanne, Switzerland | Genedata Screener 21 Further Accelerates Project Cycles and Elevates Output Quality Matthias Fassler, Product Manager Genedata Screener, Genedata, Basel, Switzerland | Streamlining Data Analysis in LC-MS MAM Workflows Patrick Merkle, Senior Expert, Novartis, Basel, Switzerland | Deciphering the Immune System's Complexity with Single-Cell and Spatial Analysis | NGS Implementation for Adventitious Virus Detection – from Investigation to Quality Control Aurora Signorazzi, Scientist & Project Leader, Janssen, Leiden, The Netherlands | ||
| 3:30–4:00 | Unifying Antibody Library Workflows Including NGS Analysis in Genedata Biologics Nathalie George, Investigator, Novartis, Basel, Switzerland | A Window to the RNA Landscape: Optimizing Analysis of Gene Expression Assays at Axxam | Genedata Expressionist at Biologics Research Center (BRC) Basel Christian Hug & Emilie Muller, Heloise Hensinger & Thierry Besson, Novartis, Basel, Switzerland | The NGS Analysis Pipelines for Virus Detection in Biologics Izabela Fabianska, Scientist Development Analytics, IDT Biologika, Dessau-Rosslau, Germany | |||
| 4:00–4:15 | Break | ||||||
| 4:15–5:30 | Demo and Poster Session Meet the Experts – Check out our demos and view posters. Demos are approximately 5–10 minutes and will be repeated on demand throughout the session. | ||||||
| Breakout Sessions | |||||||
| BIOTHERAPEUTICS DISCOVERY & DEVELOPMENT Biologics & Bioprocess | NGS-BASED DEVELOPMENT & BIOSAFETY Selector | ||||||
| 5:30–6:00 | Automation of Upstream Process Development in Genedata Bioprocess at Biotalys | Enabling the Validation of NGS-Based Characterization and Release Assays | |||||
| 6:00–6:30 | Roadmap Genedata Biologics & Genedata Bioprocess Christoph Freiberg, Head of Science, Genedata, Basel, Switzerland Guido Cappuccilli, Product Manager, Genedata, Basel, Switzerland | Panel Discussion: NGS in an Evolving Regulatory Landscape | |||||
| 7:00 | Dinner Restaurant Kunsthalle, Steinenberg 7, 4051 Basel | ||||||
| Day 2 — Thursday, March 7, 2024 | |||
| Plenary Session | |||
| 8:00–8:45 | Welcome Coffee Hyperion Hotel Basel, Messeplatz 12, Basel, Switzerland | ||
| 8:45–9:00 | Opening Remarks Jana Hersch, Head of Corporate Scientific Engagement, Genedata, Boston, MA, USA | ||
| 9:00–9:30 | Analytical Tools for Modern Integrated Drug Discovery Jonathan Wingfield, Principal Scientist, AstraZeneca, Cambridge, UK | ||
| 9:30–10:00 | Automating MS-Based Bioanalytics Workflows with Genedata at Novartis Felix Stemmer, Senior Scientist II, and Martin Jockel, Senior Expert I Data Science, Novartis, Basel, Switzerland | ||
| 10:00–10:30 | Break | ||
| 10:30–11:00 | AI-Based Digital Pathology Image Classification Sven-Eric Schelhorn, Associate Director Oncology Data Science, Merck, Darmstadt, Germany | ||
| 11:00–11:30 | GSK’s Biopharma Data Platform for End-to-End Data Science, Analytics, and Lab Automation Workflows Thil Batuwangala, Director Data Sciences – Large Molecule Discovery, and Przemyslaw Stasica, Biopharma Discovery Data Designer, GSK, Stevenage, United Kingdom | ||
| 11:30–12:00 | Discovery & Optimization of Biotherapeutics — towards Higher Throughput Peptide Mapping Using Mass Spectrometry Jennifer Kuehn, Lab Head Assays & Analytics, Sanofi, Frankfurt am Main, Germany | ||
| 12:00–12:45 | Panel Discussion — Beyond Automation: How to Build a Corporate Culture of Data Quality | ||
| 12:45–2:00 | Lunch Hyperion Hotel Basel | ||
| Breakout Sessions | |||
| BIOTHERAPEUTICS DISCOVERY & DEVELOPMENT Biologics & Bioprocess | ASSAY ANALYSIS & MANAGEMENT Screener | MASS-SPEC DATA ANALYSIS Expressionist | |
| 2:00–2:30 | AbbVie Digitalization Journey with Genedata Sukru Kaymakcalan, Director of Information Research and Technology Solutions, AbbVie, Worcester, MA, USA | High Dimensional Analysis of Cell Paint Data in Genedata Screener | Unraveling the Complete Picture of Disulfide Linkages in IgGs Sipke Sangers, Principal Scientist Analytical Sciences Mass Spectrometry, Genmab, Utrecht, The Netherlands |
| 2:30–3:00 | Our Journey Deploying Genedata Biologics at ADC Therapeutics Christopher Gallagher, Associate Director, ADC Therapeutics, London, United Kingdom | Accelerating Time to Market through Digitalization of Automation Workflows Sascha Fischer, Business Development Manager, Genedata, Switzerland | Investigation of In Vivo Biotransformations of Biotherapeutics in Mouse Plasma Using Intact and Middle-Down MS Jonathan Dhenin, Senior Scientist Metabolism DMPK Research Platform, Sanofi, Paris, France |
| 3:00–3:30 | Break | ||
| 3:30–4:00 | Integration of Genedata Bioprocess with CellCelector for Increasing Automation and Throughput in Sartorius’ CLD Platform Markus Sanna, Manager Digital Data Excellence and IT Services, Sartorius, Ulm, Germany | Novel Analysis Methodology Using Genedata Screener to Understand Neuronal Phenotypes on Multi-electrode Array (MEA) Amy Brook, Associated Research Leader, Charles River Laboratories, Saffron Walden, United Kingdom | Tailored MS Data Processing Workflows for Analyzing ADCs from Hit Discovery to Lead Optimization |
| 4:00–4:30 | Bispecific Antibodies at Light Chain Bioscience — from Discovery to Clinical Development Walter Ferlin, CSO, Light Chain Bioscience, Geneva, Switzerland | Towards an Integrated Platform for Chromatography Data Analysis and Management | Customized Activity Development for Routine Leachables Analysis: A Case Study in the Hyphenated & Special Technology Group at Roche Nicolas Wernli, Technical Lead, and Covadonga Palacio Gutierrez, Scientist, Roche, Basel, Switzerland |
| End of Symposium | |||